Generation of more effective cancer vaccines

References

• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst 2002; 94:805 - 18; http://dx.doi.org/10.1093/jnci/94.11.805; PMID: 12048268
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909 - 15; http://dx.doi.org/10.1038/nm1100; PMID: 15340416
   PubMed Web of Science ®Google Scholar
• Yang JC. Melanoma vaccines. Cancer J 2011; 17:277 - 82; http://dx.doi.org/10.1097/PPO.0b013e3182325f72; PMID: 21952276
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205 - 16; http://dx.doi.org/10.1093/jnci/92.3.205; PMID: 10655437
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148 - 59; http://dx.doi.org/10.1200/JCO.2007.12.4487; PMID: 18309951
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624; PMID: 19934295
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M. Immunotherapy of melanoma. Semin Cancer Biol 2003; 13:391 - 400; http://dx.doi.org/10.1016/j.semcancer.2003.09.001; PMID: 15001157
   PubMed Web of Science ®Google Scholar
• Aly HA. Cancer therapy and vaccination. J Immunol Methods 2012; 382:1 - 23; http://dx.doi.org/10.1016/j.jim.2012.05.014; PMID: 22658969
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254 - 61; http://dx.doi.org/10.1038/nm.2883; PMID: 22842478
   PubMed Web of Science ®Google Scholar
• Haen SP, Rammensee HG. The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. Curr Opin Immunol 2013; 25:277 - 83; http://dx.doi.org/10.1016/j.coi.2013.03.007; PMID: 23619309
   PubMed Web of Science ®Google Scholar
• Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7:881 - 7; http://dx.doi.org/10.1586/14760584.7.7.881; PMID: 18767939
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13:5991 - 4; http://dx.doi.org/10.1158/1078-0432.CCR-07-0686; PMID: 17947459
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 2013; 62:1041 - 52; http://dx.doi.org/10.1007/s00262-013-1415-9; PMID: 23591981
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385; PMID: 21918169
   PubMed Web of Science ®Google Scholar
• Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60:1553 - 64; http://dx.doi.org/10.1007/s00262-011-1061-z; PMID: 21681371
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19:990 - 9; http://dx.doi.org/10.1038/mt.2010.289; PMID: 21189474
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008; 31:771 - 80; http://dx.doi.org/10.1097/CJI.0b013e3181833818; PMID: 18779742
   PubMed Web of Science ®Google Scholar
• Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007; 5:12; http://dx.doi.org/10.1186/1479-5876-5-12; PMID: 17324292
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127 - 33; PMID: 12727829
   PubMed Web of Science ®Google Scholar
• Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71:1253 - 62; http://dx.doi.org/10.1158/0008-5472.CAN-10-2693; PMID: 21216894
   PubMed Web of Science ®Google Scholar
• Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012; 1:670 - 86; http://dx.doi.org/10.4161/onci.20426; PMID: 22934259
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188:97 - 113; http://dx.doi.org/10.1034/j.1600-065X.2002.18809.x; PMID: 12445284
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells forPatients with Metastatic Melanoma (E1602). [Epub ahead of print] Clin Cancer Res 2013; http://dx.doi.org/10.1158/1078-0432.CCR-13-0002
   Web of Science ®Google Scholar
• Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013; 104:15 - 21; http://dx.doi.org/10.1111/cas.12050; PMID: 23107418
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62:125 - 35; http://dx.doi.org/10.1007/s00262-012-1319-0; PMID: 22847020
   PubMed Web of Science ®Google Scholar
• Nunes-Xavier CE, Martín-Pérez J, Elson A, Pulido R. Protein tyrosine phosphatases as novel targets in breast cancer therapy. Biochim Biophys Acta 2013; 1836:211 - 26; PMID: 23756181
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685 - 92; http://dx.doi.org/10.1200/JCO.2008.20.6789; PMID: 19720923
   PubMed Web of Science ®Google Scholar
• Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588 - 94; http://dx.doi.org/10.1016/S0952-7915(98)80228-8; PMID: 9794842
   PubMed Web of Science ®Google Scholar
• Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999; 96:8633 - 8; http://dx.doi.org/10.1073/pnas.96.15.8633; PMID: 10411927
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357 - 68; http://dx.doi.org/10.1084/jem.188.12.2357; PMID: 9858522
   PubMed Web of Science ®Google Scholar
• Ossendorp F, Mengedé E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187:693 - 702; http://dx.doi.org/10.1084/jem.187.5.693; PMID: 9480979
   PubMed Web of Science ®Google Scholar
• Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010:1; http://dx.doi.org/10.1155/2010/596432; PMID: 20706612
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838 - 47; http://dx.doi.org/10.1056/NEJMoa0810097; PMID: 19890126
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114 - 9; http://dx.doi.org/10.1016/S0952-7915(00)00191-6; PMID: 11154927
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30:16 - 34; http://dx.doi.org/10.3109/08830185.2010.529976; PMID: 21235323
   PubMed Web of Science ®Google Scholar
• Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011; 366:2748 - 55; http://dx.doi.org/10.1098/rstb.2011.0106; PMID: 21893536
   PubMed Web of Science ®Google Scholar
• Dubensky TW Jr., Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010; 22:155 - 61; http://dx.doi.org/10.1016/j.smim.2010.04.007; PMID: 20488726
   PubMed Web of Science ®Google Scholar
• Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150 - 82; http://dx.doi.org/10.3109/08830185.2011.572210; PMID: 21557641
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1:111 - 8; http://dx.doi.org/10.1586/14760584.1.1.111; PMID: 12908518
   PubMed Web of Science ®Google Scholar
• Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol 2007; 157:Suppl 2 8 - 13; http://dx.doi.org/10.1111/j.1365-2133.2007.08265.x; PMID: 18067624
   PubMed Web of Science ®Google Scholar
• Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?. J Control Release 2010; 148:266 - 82; http://dx.doi.org/10.1016/j.jconrel.2010.09.018; PMID: 20869998
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464 - 78; http://dx.doi.org/10.1016/j.immuni.2010.10.007; PMID: 21029958
   PubMed Web of Science ®Google Scholar
• Church SE, Jensen SM, Twitty CG, Bahjat K, Hu HM, Urba WJ, Fox BA. Multiple vaccinations: friend or foe. Cancer J 2011; 17:379 - 96; http://dx.doi.org/10.1097/PPO.0b013e3182346320; PMID: 21952289
   PubMed Web of Science ®Google Scholar
• Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013; 00024 - 9; PMID: 23706598
   PubMedGoogle Scholar
• Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11:805 - 12; http://dx.doi.org/10.1038/nrc3153; PMID: 22020206
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18:11 - 8; http://dx.doi.org/10.1016/j.gde.2007.12.007; PMID: 18308558
   PubMed Web of Science ®Google Scholar
• Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179:4323 - 34; PMID: 17878327
   PubMed Web of Science ®Google Scholar
• Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, Ferrera F, Proietti M, Tardito S, Sanguineti M, Millo E, et al. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. J Transl Med 2013; 11:120; http://dx.doi.org/10.1186/1479-5876-11-120; PMID: 23663506
   PubMed Web of Science ®Google Scholar